Physician profile
Mariah C Grace
NPI 1164727368
$486.44
in general payments reported to CMS, 2019-2025
13 companies · $34.20 in 2025
The $34.20 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $37.96 · 2021: $84.75 · 2022: $54.46 · 2023: $225 · 2024: $50.32 · 2025: $34.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $131.60 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $63.69 | 2021-2022 | |
| Therapeuticsmd, INC. | $54.28 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $37.21 | 2023 | |
| Aspira Women'S Health INC | $34.37 | 2023 | Ova1 |
| Organon LLC | $31.17 | 2022 | |
| Coopersurgical, INC. | $28.03 | 2021 | |
| Sumitomo Pharma America, INC. | $25.98 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $23.56 | 2023 | Phexxi |
| Millicent US INC | $17.50 | 2025 | Femring, Intrarosa |
| Exeltis, USA INC. | $16.70 | 2025 | Slynd |
| Pfizer INC. | $14.13 | 2023 | |
| Meditrina | $8.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.